Software as a Drug

By | NEWS | No Comments

What if your spouse were a borderline Type 2 diabetic?  If you had the money, you could hire someone to follow her or him around the clock, sort of like a glorified personal trainer.  Your spouse would make sure he or she took a daily mile-long walk, did some weight training to build muscle mass and would stop you from eating ice cream or cake or drinking a glass of wine. Read More

Gamma Medica Announces New Partnership in the Fight Against Breast Cancer with Henry Ford Health System LP

By | NEWS | No Comments

WEST BLOOMFIELD, Michigan & SALEM, N.H. – (Nov. 3, 2016 ) Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced that Henry Ford Health System has purchased Gamma Medica’s LumaGEM Molecular Breast Imaging system. The system is set to be installed by the end of 2016 at Henry Ford West Bloomfield Hospital. The MBI technology will be offered as a secondary screening and diagnostic tool following X-ray mammography, particularly for women with dense breast tissue. This proven imaging modality will help improve cancer detection in women who are at greater risk of developing breast cancer. Read More

Market for digital therapeutics looks healthy

By | NEWS | No Comments

Digital-Therap-Small-Alastair-161012-300x262

By Tom York for VC Journal

Digital therapeutics, combining remote patient monitoring, behavior modification, wearables, data analytics and related technologies to treat patients with chronic conditions, has been big on promises but short on delivery, despite the best efforts of a number of venture-backed companies in the sector.

But that’s about to change and for the better, according to a report from the New York healthcare-focused venture firm Psilos Group.

The digital-therapeutics market could jump to $6.8 billion in 2021, 11 times the $599 million of 2016, the report says.

To be sure, the projected amount is but a sliver of the $3.25 trillion spent on healthcare in the United States in 2015. But Psilos Managing Partner Joe Riley said the report’s optimism is based on the success of several VC-backed early-stage companies entering the market.

“There are a lot of firms like ourselves who are starting to grasp the importance of digital therapeutics in terms of addressing the rising cost of healthcare and a new way to attack chronic illnesses,” he said. “Until this point, we’ve just scratched the surface on how to address these problems.”

Psilos invested in two rounds in eight-year-old Healthmine (formerly SeeChange Health). The Dallas company uses analytics to scour tens of thousands of health-plan medical records, lab reports and wearable devices to track such conditions as abnormal heart rates and high glucose levels. It then suggests treatments.

The company claims it’s saved employers more than $100 million to date.

Despite such numbers, not all VCs say the market is poised for rapid growth, due to cumbersome federal regulations and approval processes.

Robert Mittendorff, an emergency physician and a partner at Norwest Venture Partners, agreed with the Psilos report that the digital-therapeutics sector would continue to expand. But he expects a less accelerated pace.

In September 2015, Norwest led a $48 million Series C round in Omada Health, one of the more talked-about startups in the sector.

Other firms joining in the third round included Andreessen HorowitzdRX CapitalGE VenturesHumanaProvident Health & ServicesRock Health andU.S. Venture Partners.

Counselors at the San Francisco startup work with patients to help with such challenges as diet and exercise to mitigate the impact of type 2 diabetes.

“Digital therapeutics is happening, and we’re seeing proof that it works,” Mittendorff said.

What’s getting in the way of the sector’s growth is that these businesses aren’t being reimbursed “out of the standard coffers from which the majority of healthcare is paid for by insurance companies,” Mittendorff said. “But the process of convincing insurers to pay for it is on its way.”

Tom York is a San Diego-based contributor.

Dallas-Based HealthMine, a Psilos Portfolio Company, Featured in 2016 Outlook Report

By | NEWS | No Comments

NEW YORK, NY–(Marketwired – Oct 6, 2016) – Psilos Group, in its seventh annual OUTLOOK outlining major emerging healthcare trends, says digital therapeutics is a $6 billion market opportunity by 2021. Digital therapeutics — “software as a drug” — deploys software modules as an enhancement, or even a substitute, to a drug. It is poised to become a critical component of digital health and to substantially improve the efficiency of American healthcare. Read More

Psilos Group: Digital Therapeutics — “Software as a Drug” — Is a $6 Billion Potential Market Opportunity Says 2016 Outlook Report

By | NEWS | No Comments
Utilizing Software Modules as an Enhancement to Pharmaceuticals for Chronic Conditions Is Poised to Be Critical Component of Digital Healthcare

NEW YORK, NY — (Marketwired) — 10/06/16 — Psilos Group, in its seventh annual OUTLOOK outlining major emerging healthcare trends, says digital therapeutics is a $6 billion market opportunity by 2021. Digital therapeutics — “software as a drug” — deploys software modules as an enhancement, or even a substitute, to a drug. It is poised to become a critical component of digital health and to substantially improve the efficiency of American healthcare.

Read More

The Arizona Republic Features 2016 Psilos Outlook Report

By | NEWS | No Comments

NEW YORK, NY — (Marketwired) — 10/06/16 — Psilos Group, in its seventh annualOUTLOOK outlining major emerging healthcare trends, says digital therapeutics is a $6 billion market opportunity by 2021. Digital therapeutics — “software as a drug” — deploys software modules as an enhancement, or even a substitute, to a drug. It is poised to become a critical component of digital health and to substantially improve the efficiency of American healthcare. Read More